Preclinical efficacy of CDK7 inhibitor-based combinations in cellular models of advanced myeloproliferative neoplasms (MPN)

被引：0
|
作者：
Mill, Christopher P.
Fiskus, Warren C.
Birdwell, Christine E.
Davis, John A.
Das, Kaberi
Bhalla, Kapil N.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-6285
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6285
引用
收藏
页数：2
相关论文
共 18 条
  • [1] Pre-Clinical Efficacy of CDK7 Inhibitor-Based Combinations in Cellular Models of Advanced Myeloproliferative Neoplasms (MPN) Transformed to AML
    Fiskus, Warren C.
    Bose, Prithviraj
    Masarova, Lucia
    Mill, Christopher Peter
    Birdwell, Christine
    Davis, John
    Das, Kaberi
    Hou, Hanxi
    Manshouri, Taghi
    Philip, Kevin
    Alhamadani, Noor
    Matthews, Alicia
    Loghavi, Sanam
    Bhalla, Kapil N.
    BLOOD, 2023, 142
  • [2] Efficacy of CDK9 inhibitor-based combinations as therapy for post-myeloproliferative neoplasm (MPN) secondary (s) AML
    Saenz, Dyana T.
    Fiskus, Warren C.
    Manshouri, Taghi
    Mill, Christopher P.
    Khoury, Joseph D.
    Verstovsek, Srdan
    Bhalla, Kapil N.
    CANCER RESEARCH, 2019, 79 (13)
  • [3] Preclinical Studies Demonstrating Efficacy of Tasquinimod in Models of Advanced Myeloproliferative Neoplasm (MPN) in Blastic Phase
    Fiskus, Warren C.
    Masarova, Lucia
    Mill, Christopher Peter
    Birdwell, Christine
    Das, Kaberi
    Davis, John
    Hou, Hanxi
    Alhamadani, Noor
    Philip, Kevin
    Matthews, Alicia
    Manshouri, Taghi
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Bose, Prithviraj
    Pemmaraju, Naveen
    Loghavi, Sanam
    Torngren, Marie
    Bhalla, Kapil N.
    BLOOD, 2023, 142
  • [4] SY5609, a Potent and Selective CDK7 Inhibitor, Potentiates BTK Inhibitor Activity in Mantle Cell Lymphoma Preclinical Models
    Johannessen, Liv
    Henry, Susan
    Sawant, Priyanka
    D'Ippolito, Anthony
    Ke, Nan
    Lefkowitz, Ariel
    Eaton, Matthew
    Dworakowski, Wojciech
    Rosario, Maria
    Hodgson, Graeme
    BLOOD, 2021, 138
  • [5] Activity of SY-5609, an oral, noncovalent, potent, and selective CDK7 inhibitor, in preclinical models of colorectal cancer.
    Johannessen, Liv
    Ke, Nan
    Sawant, Priyanka
    Dworakowski, Wojciech
    D'Ippolito, Anthony
    Hu, Shanhu
    Rajagopal, Nisha
    Eaton, Matthew
    Hodgson, Graeme
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma
    Dengler, Michael A.
    Teh, Charis E.
    Thijssen, Rachel
    Gangoda, Lahiru
    Lan, Ping
    Herold, Marco J.
    Gray, Daniel H.
    Kelly, Gemma L.
    Roberts, Andrew W.
    Adams, Jerry M.
    ONCOGENE, 2020, 39 (09) : 2009 - 2023
  • [7] Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma
    Michael A. Dengler
    Charis E. Teh
    Rachel Thijssen
    Lahiru Gangoda
    Ping Lan
    Marco J. Herold
    Daniel H. Gray
    Gemma L. Kelly
    Andrew W. Roberts
    Jerry M. Adams
    Oncogene, 2020, 39 : 2009 - 2023
  • [8] Preclinical evaluation of KRLS-017, a potent, highly selective and reversible CDK7 inhibitor with broad antitumor effect in preclinical models, in preparation for a Phase 1 clinical trial in advanced solid tumor malignancies
    Hannah, Alison L.
    Ritland, Steve
    Steele, Thomas
    Smith, Steven
    Ram, Ashwin
    Slingsby, B. T.
    Dhingra, Kapil
    Chrisman, James
    Dua, Rajesh
    Tokunaga, Yasunori
    Kono, Shigeyuki
    Aga, Yasuhiro
    CANCER RESEARCH, 2023, 84 (06)
  • [9] SY-1365, a potent and selective CDK7 inhibitor, exhibits promising anti-tumor activity in multiple preclinical models of aggressive solid tumors
    Hu, Shanhu
    Ke, Nan
    Ren, Yixuan
    Miljovska, Sofija
    Rajagopal, Nisha
    McKeown, Michael
    Orlando, David
    Sprott, Kevin
    Choi, Yoon J.
    Olson, Eric
    Fritz, Christian C.
    CANCER RESEARCH, 2017, 77
  • [10] PK/PD modeling of the first in-class, potent and selective covalent CDK7 inhibitor, SY-1365, provides mechanistic basis for intermittent dosing regimens in preclinical efficacy models of hematologic and solid tumors
    Waters, Nigel J.
    Hu, Shanhu
    Matzuka, Brett
    Hodgson, Graeme
    Ren, Yixuan
    Choi, Yoon
    Dykstra, Kevin
    Roberts, Christopher
    Sprott, Kevin
    di Tomaso, Emmanuelle
    Fritz, Christian
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
12